Biomerica, Inc. has secured its first commercial order for the HP Detect diagnostic test in Europe, marking progress in international expansion. Despite this, the company continues to report operating losses, though these have narrowed compared to previous years. Regulatory approvals across diverse geographies and reimbursement codes support growth prospects, while recent CFO resignation introduces potential operational risks. Capital allocation remains focused on preserving liquidity and funding growth initiatives without dividends or share buybacks.